A senior FDA scientist has told federal hearings something many advocates of medical cannabis would rather not hear. When it comes to marijuana PTSD risks, the government’s own review found the dangers outweigh any proven benefit. Even so, that conclusion lands awkwardly. Marijuana is already being used, and marketed, as a treatment for the condition across the United States.

The admission came during testimony at the DEA’s ongoing marijuana rescheduling hearings, first reported by The Drug Report. Dr Dominic Chiapperino leads the FDA’s rescheduling review. He explained that the agency only needed to find one condition with a currently accepted medical use to justify moving marijuana out of Schedule I. His team examined seven conditions in total. Only three cleared that bar: pain, appetite loss tied to a medical condition, and nausea and vomiting, usually linked to chemotherapy.

Why PTSD Failed the Test

Four conditions did not make the cut. PTSD was among them, alongside anxiety, epilepsy and inflammatory bowel disease. Chiapperino was asked directly whether the FDA had concluded that cannabis PTSD treatment carries risks that outweigh its benefits. He agreed that it had. Notably, he also acknowledged something surprising. PTSD is one of the most common reasons Americans are currently using medical marijuana, which makes the finding harder to ignore rather than easier.

The FDA’s own recommendation document backs up his testimony. Outside contractors rated the PTSD evidence as low to moderate quality. However, the agency’s broader review found mixed results overall. It concluded that the potential for psychiatric adverse events linked to treating PTSD with marijuana may be more substantial than any limited benefit on offer.

A Thin Evidence Base

The numbers behind that conclusion are striking. Of roughly 4,500 studies screened for PTSD, only one randomised controlled trial and one observational study met the FDA’s quality threshold. That single trial was the strongest piece of evidence available. Even so, it found marijuana performed no better than a placebo at easing PTSD symptoms.

Chiapperino went further still. He conceded that for the conditions the FDA chose not to evaluate at all, nobody should assume there is evidence to support their use. In other words, the absence of a formal review is not a quiet endorsement. It is simply an absence.

The Gap Between Policy and Practice

This matters well beyond a hearing room. In practice, marijuana PTSD risks have real consequences for people already living with trauma. Many have been told, by dispensary staff, online forums or word of mouth, that cannabis is a safe option for their symptoms. The government’s own scientists reached the opposite conclusion after sifting through thousands of studies. Yet that message rarely reaches the people making decisions about their own care.

The disconnect is not new. Overall, medical claims around cannabis have consistently outpaced the evidence supporting them. PTSD may be the clearest example yet. A condition defined by anxiety, intrusive memories and disrupted sleep is being treated, informally and at scale, with a substance the FDA’s own review links to a heightened risk of psychiatric adverse events.

What Comes Next

The rescheduling hearings continue. Meanwhile, marijuana’s status under federal law may yet shift on the strength of the three conditions that did clear the bar. But Chiapperino’s testimony leaves little room for ambiguity on PTSD specifically. Until stronger evidence emerges, people managing trauma deserve treatments that have been properly tested. They should not rely on the assumption that everyone else is already using cannabis safely.

Anyone currently using or considering cannabis PTSD treatment for trauma related symptoms should talk to a qualified health professional about options backed by proper clinical evidence. The marijuana PTSD risks identified in this review are a reminder that popularity is not the same thing as proof.

Source: thedrugreport